8-K: Arvinas and Pfizer Announce Positive Initial Phase 1b Data for Vepdegestrant and Abemaciclib Combination in Breast Cancer

Arvinas and Pfizer reported encouraging preliminary results from a Phase 1b study of vepdegestrant combined with abemaciclib for advanced breast cancer, showing a tolerable safety profile and a 62.5% clinical benefit rate.

Summary

• Arvinas and Pfizer have announced preliminary data from a Phase 1b study of vepdegestrant in combination with abemaciclib for patients with advanced breast cancer.
• The study included 16 patients with locally advanced or metastatic ER+/HER2breast cancer who had previously been treated with a CDK4/6 inhibitor.
• The combination of vepdegestrant (200mg QD) and abemaciclib (150mg BID) demonstrated a tolerable safety profile.
• A clinical benefit rate (CBR) of 62.5% was observed across all patients, including those with both mutant and wild-type ESR1.
• The objective response rate (ORR) was 26.7% overall, with 37.5% in patients with mutant ESR1 and 14% in patients with wild-type ESR1.
• Pharmacokinetic data showed no significant drug-drug interaction between the two drugs.
• The safety profile was consistent with the known properties of abemaciclib and previous vepdegestrant trials.
• These results support the ongoing Phase 2 portion of the study.

Sentiment

Score: 8

Explanation: The document presents positive preliminary data with a strong clinical benefit rate and tolerable safety profile, suggesting a promising outlook for the combination therapy. The management comments are also positive, further boosting the sentiment.

Positives

• The combination therapy demonstrated a strong clinical benefit rate of 62.5% in a challenging patient population.
• The safety profile of the combination was found to be tolerable and consistent with expectations.
• No significant drug-drug interaction was observed, which is a positive sign for combination therapy.
• The study supports the progression to Phase 2 trials with the identified dose.

Negatives

• The objective response rate was 26.7% overall, which may be considered moderate.
• The objective response rate was lower in patients with wild-type ESR1 (14%) compared to those with mutant ESR1 (37.5%).
• The most common adverse events were diarrhea, nausea, and fatigue, which are typical for these types of treatments.

Risks

• The results are preliminary and from a small Phase 1b study, so further data from Phase 2 is needed to confirm these findings.
• The success of the Phase 2 trial is not guaranteed, and the combination may not show the same efficacy or safety profile in a larger patient population.
• Regulatory approval is not guaranteed, and the drug may not be approved for commercialization.
• There are risks associated with the development and commercialization of new drugs, including competition and market acceptance.

Future Outlook

The companies are continuing to evaluate data from the ongoing TACTIVE-U clinical trial, which includes combinations of vepdegestrant plus abemaciclib, ribociclib or samuraciclib. The Phase 2 portion of the study is ongoing, evaluating the combination of full dose abemaciclib with vepdegestrant in post-CDK4/6 advanced breast cancer.

Management Comments

• Noah Berkowitz, M.D., Ph.D., Chief Medical Officer at Arvinas, stated that the preliminary results are encouraging and reinforce their belief that vepdegestrant can be used in multiple combination regimens.
• Roger Dansey, M.D., Chief Development Officer, Pfizer, mentioned that they aim to develop vepdegestrant as a new backbone endocrine therapy in ER+ metastatic breast cancer.

Industry Context

This announcement is significant in the context of the ongoing search for effective treatments for advanced breast cancer, particularly for patients who have progressed after CDK4/6 inhibitor therapy. The combination of a PROTAC ER degrader with a CDK4/6 inhibitor represents a novel approach to addressing this unmet need. Several companies are developing similar therapies, making this a competitive space.

Comparison to Industry Standards

• The clinical benefit rate of 62.5% is promising when compared to other treatments for advanced breast cancer after CDK4/6 inhibitor failure, such as single-agent endocrine therapies or chemotherapy.
• The objective response rate of 26.7% is within the range of what is seen with other targeted therapies in this setting, but the 37.5% ORR in mutant ESR1 patients is particularly encouraging.
• Companies like Radius Health with elacestrant and AstraZeneca with capivasertib are also developing therapies for this patient population, and the results of this study will be closely watched in comparison to those.

Stakeholder Impact

• Shareholders may react positively to the encouraging clinical data.
• Patients with advanced breast cancer may benefit from this potential new treatment option.
• Employees of Arvinas and Pfizer may be motivated by the positive results.
• The medical community will be interested in the further development of this combination therapy.

Next Steps

• The companies will continue to evaluate data from the ongoing TACTIVE-U clinical trial.
• The Phase 2 portion of the study will continue, evaluating the combination of full dose abemaciclib with vepdegestrant.
• Further data will be presented at future medical conferences.

Key Dates

Keywords

Vepdegestrant, Abemaciclib, Breast Cancer, PROTAC, ER Degrader, Phase 1b, Clinical Trial, Metastatic, ER+, HER2-, CDK4/6 Inhibitor, Combination Therapy